These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216 [TBL] [Abstract][Full Text] [Related]
5. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768 [TBL] [Abstract][Full Text] [Related]
6. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730 [TBL] [Abstract][Full Text] [Related]
7. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. Gakovic M; Ragimbeau J; Francois V; Constantinescu SN; Pellegrini S J Biol Chem; 2008 Jul; 283(27):18522-9. PubMed ID: 18456658 [TBL] [Abstract][Full Text] [Related]
10. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation. Bock O; Hussein K; Neusch M; Schlué J; Wiese B; Kreipe H Eur J Haematol; 2006 Dec; 77(6):463-70. PubMed ID: 16930139 [TBL] [Abstract][Full Text] [Related]
11. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients]. Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533 [TBL] [Abstract][Full Text] [Related]
12. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. Turakhia SK; Murugesan G; Cotta CV; Theil KS J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830 [TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Hexner EO Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351 [TBL] [Abstract][Full Text] [Related]
14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
15. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672 [TBL] [Abstract][Full Text] [Related]
16. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308 [TBL] [Abstract][Full Text] [Related]
17. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922 [TBL] [Abstract][Full Text] [Related]
18. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582 [TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]